TRVN Trevena, Inc.

2.49
-0.03  -1%
Previous Close 2.52
Open 2.58
Price To book 2.14
Market Cap 145.17M
Shares 58,301,000
Volume 623,292
Short Ratio 7.49
Av. Daily Volume 626,202

SEC filingsSee all SEC filings

  1. 8-K - Current report 17916282
  2. 8-K - Current report 17857780
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814340
  4. 8-K - Current report 17811762
  5. DEF 14A - Other definitive proxy statements 17734293

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 APOLLO-1 and APOLLO-2 data released February 21, 2017 - primary endpoints met but commercial doubts raised. NDA filing due 4Q 2017.
Oliceridine (TRV130)
Moderate to severe acute pain
Phase 2b endpoints not met - May 2016
TRV027 - BLAST-AHF
Acute heart failure

Latest News

  1. Trevena Attends National Institutes of Health Meeting to Discuss Development of Novel, Improved Pain Medications
  2. Trevena to Present at Investor Conferences in June
  3. Trevena Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  4. Trevena Announces Presentations During the 36th Annual Scientific Meeting of the American Pain Society
  5. Why You're Smart to Buy Cara Therapeutics Stock
  6. Trevena reports 1Q loss
  7. Trevena Reports First Quarter 2017 Financial Results and Provides Corporate Update
  8. ETFs with exposure to Trevena, Inc. : May 2, 2017
  9. Trevena to Present at the Deutsche Bank Securities 42nd Annual Healthcare Conference
  10. ETFs with exposure to Trevena, Inc. : April 7, 2017
  11. Trevena, Synergy Lead Biotech Movers
  12. Trevena Announces Presentations at the 42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting
  13. Trevena to Present at Needham & Company’s 16th Annual Healthcare Conference
  14. Lifshitz & Miller LLP Announces Investigation of Argos Therapeutics, Inc., Avid Technology, Inc., HMS Holdings Corp., Invuity, Inc., SITO Mobile, Ltd., Trevena, Inc., USANA Health Sciences, Inc. and VAALCO Energy, Inc.
  15. What Makes Trevena (TRVN) a Strong Sell?
  16. Trevena, Inc. :TRVN-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
  17. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Trevena, Inc. (TRVN)
  18. TREVENA (TRVN) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Trevena, Inc.; Investors Encouraged to Contact Firm
  19. INVESTOR ALERT: Investigation of Trevena Announced by Holzer & Holzer, LLC

SEC Filings

  1. 8-K - Current report 17916282
  2. 8-K - Current report 17857780
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 17814340
  4. 8-K - Current report 17811762
  5. DEF 14A - Other definitive proxy statements 17734293
  6. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17675732
  7. 8-K - Current report 17673884
  8. 8-K - Current report 17664164
  9. 8-K - Current report 17623431
  10. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17609633